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Background: A novel therapeutic management of osteoarthritis (OA) of the knee was assessed. The study aimed to
evaluate the effect of monthly sodium bicarbonate with a single (SBCG1) or double dose (SBCG2) of calcium gluconate
injections on OA of the knee; as well as the efficacy and safety of both SBCG interventions in the long term.
Methods: A double-blind parallel-group clinical trial with 74 knee OA patients was performed during 12 months, both
SBCG interventions were followed-up for another 6mo after intervention. The outcome variables were the Western
Ontario-McMaster University Osteoarthritis Index (WOMAC), the Lequesne’s functional index and joint-space width
changes from serial radiographs.
Results: After 12 months, group SBCG1 decreased −14.8 (95% CI:-14.2, −17.0) and group SBCG2 decreased −14.6
(−16.9, −12.4) in the global WOMAC score, the mean changes represent 80% and 82% lessened pain, respectively. In
the Lequesne Functional Index scale, SBCG1 decreased −11.9 (−10.4, −14.2) and SBCG2 decreased -11.9 (−13.8, −10.0),
representing 66 and 69% of improvement. Both mean scores were maintained after intervention discontinued. SBCG2
improved the knees’ joint space width more than SBCG1 at 3 and 18 months. Both SBCG interventions were well tolerated
after 12 months of treatment
Conclusion: A solution of sodium bicarbonate and calcium gluconate is effective on reducing the symptoms associated
with OA. Its beneficial effect is maintained for one year of continuous monthly administration and at least for 6 months
after the administration is discontinued. When the dose of calcium gluconate is increased, it prevents further narrowing
of joint-space.
Trial registration: Clinicaltrials.gov NCT00977444 September 11, 2009.
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Osteoarthritis (OA) is the most common joint disease; it
is a consequence of cartilage degradation. OA may affect
several joints, especially weight-bearing joints such as
the knees. A joint’s cartilage degradation is clinically rec-
ognized by a gradual development of pain, stiffness, and* Correspondence: jlrosado@prodigy.net.mx
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unless otherwise stated.loss of motion. Among the elderly, hip and knee OA
causes a greater degree of disability [1]. It is estimated that
9.6% of men and 18% of women above 60 years have
symptomatic OA primarily in the knees and hips [2].
Therapeutic management of OA of the knee has fo-
cused on pain relief, preserving or improving the range
of motion and preventing secondary functional disability
as well as joint damage. Besides surgery, which is recom-
mended for severe cases, there are a wide variety of OA
therapies commonly used: Non-pharmacological treat-
ments are mainly aimed to unload the joint, such asentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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OA of the knee; and pharmacological therapies which
include analgesics, nonsteroidal anti-inflammatory drugs
(NSAIDS), opioids, hyaluronic acid (HA) or corticosteroid
injections and various drugs purported as disease-
modifying osteoarthritis drugs (DMOADs) [3]. According
to a recent review of knee OA therapeutic responses, HA
injections, corticosteroids injections and opioids have
demonstrated the highest effect of the recommended
treatments [4]. However, none of these interventions have
demonstrated to halt the disease progression. Moreover,
several side effects have been demonstrated, mainly from
oral NSAIDS treatments, which have been associated with
gastrointestinal side effects [5], and opioids have been
strongly associated with constipation, nausea, vomiting, diz-
ziness, somnolence [6]. HA injections may lead to increase
medial co-contraction and accelerate joint deterioration [7].
Corticosteroid injections, although they have not demon-
strated to change the functionality of the knee, they are as-
sociated with reductions in knee pain over 2 weeks,
however, these clinical improvements disappear by 4 weeks
[8] and it is unsafe to inject it more than 4 times per year
[9]. Thus, therapies appear to be misdirected and a different
approach should be used to evaluate different alternatives.
Past research on OA treatments reported a beneficial
effect of large doses of bicarbonate on certain chronic
joint diseases; the effect was attributed to its alkalinity
[10]. Previous research also found a beneficial effect of
calcium gluconate on arthritis and other rheumatic dis-
eases, this compound operates by allowing the linkage
between chondrals and bone proteins, which avoids the
hyperosmotic and acid conditions of the extracellular
matrix and allows recovery of the homeostatic mecha-
nisms of the cartilage [11]. Therefore a pharmaceutical
solution of a combination of these two compounds
might be beneficial to treat knee OA patients.
The present study aimed to evaluate the efficacy of an
intra-articular administration of a sodium bicarbonate
solution combined with two different concentrations of
calcium gluconate injections on progression of symp-
toms and joint space width as well as the safety of these
injections in patients with knee OA.Methods
Patients
Patients eligible for the study were males and females
aged ≥40 years with at least 1 year of being diagnosed
with OA of the knee. According with the criteria of the
American College of Rheumatology, OA was confirmed
with physical exploration diagnosis of knee pain plus
one of the following: bone crackling with movement,
morning stiffness ≤15 min, age > 50 years or articular
hypertrophy. And grade II-IV knee OA was confirmedby radiology according to the Kellgren-Lawrence grading
system [12,13].
Patients diagnosed with grade I were referred for a less
invasive treatment and patients with grade IV were in-
cluded to evaluate the treatment effect in OA most ad-
vanced conditions. Three physicians examined and
diagnosed the recruited patients, two were orthopedic
specialist and one was surgeon specialized in radiology.
Exclusion criteria included: An intra-articular injection
of any substance administered within the last 3 months,
joint inflammatory diseases, microcrystalline arthropa-
thies, current pregnancy, uncontrolled hypertension, ac-
tive infection, undergone surgery/arthroscopy within the
last 3 months and diagnosis by radiography of knee OA
Kellgren and Lawrence grade I, coagulation or platelet
disorders or any concomitant disease that could interfere
with the evaluation,. Patients were enrolled by public ad-
vertising and were studied at the San José Hospital in
Queretaro, México.
The study was conducted in compliance with ICH (Inter-
national Committee of Harmonization) Good Clinical
Practices and the Declaration of Helsinki, and its applicable
amendments. It was approved by the institutional review
board for human research of the University of Querétaro
and all subjects voluntarily signed informed consent before
being enrolled in the study.
A total of 26 patients per experimental group were ne-
cessary to detect a clinically significant change of 20%
within experimental treatments, from baseline to post
treatment evaluations in the global score of Lequesne
Index and Western Ontario and McMastern University
Index (WOMAC) indexes considering an estimated
standard deviation of 35%, a two-sided alpha level of
0.05 and a statistical power of 0.8. Considering a possible
drop-out rate of 35%, 72 patients had to be recruited. In
addition, the mentioned sample size can find a signifi-
cant difference of 30% between two experimental
groups’ changes in the global score of Lequesne and
WOMAC. The parameters used to calculate the sample
size were estimated from the results of a pilot study pre-
viously carried out with 18 participants.
Study design
The study was a randomized, double-blind, parallel-
design clinical trial. Patients were followed up during
12 months with treatments and for 6 months after inter-
vention to evaluate a longer term effect and safety of the
treatment. Subjects who met the selection criteria were
randomly assigned to receive one of two treatments in
both knees (except for 2 patients with prosthesis only
one knee was intervened): 1) Sodium bicarbonate and
calcium gluconate (SBCG1) 2) Sodium bicarbonate and
a double dose of calcium gluconate (SBCG2). The
randomization method was based on a list of randomly
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puting program [14]. One researcher that had no direct
contact with patients created the randomization list and
delivered it to each physician that examined the patients
who were assigned to each physician in a systematic
order. The treatment was administered to each patient
every 30 days by one of the 3 trained and experienced
physicians who followed the same patients throughout
the study. In the baseline evaluation and in the monthly
scheduled visits during intervention period and post-
intervention follow-up, patients were clinically evaluated
with the WOMAC and Lequesne questionnaires and
also monitored for adverse events. All the fieldwork
personnel were blinded to the treatments.
Knee radiographs were taken to each patient at base-
line, after 3 months, after 12 months of intervention and
also after 6 months of post-intervention follow up. Pa-
tients were not permitted to receive concomitant treat-
ment with analgesic or systemic corticosteroids.
Treatments
The treatments were identical in packaging, labeling, sched-
ule of administration and appearance. Both treatments,
SBCG1 and SBCG2 were pharmaceutical compositions in
aqueous solution (5 mL) ready for intra-articular infrapatel-
lar injection. They were prepared at the pilot plant of the
Center for Research and Technological Development in
Chronic Disease (Cindetec A.C.). The SBCG1 treatment
was a solution with sodium bicarbonate and calcium
gluconate, both at a concentration of 7.5% (w/v); and
SBCG2 had the same concentration of sodium bicarbon-
ate than SBCG1, while the concentration of calcium glu-
conate was 15% (w/v).
Efficacy assessments
The primary efficacy outcome variables were the
changes from baseline to post-intervention assessments
in the WOMAC, and Lequesne’s functional indexes and
joint space width.
The WOMAC OA index is a validated, multidimen-
sional, disease specific, health status measure. It provides
with clinically important patient relevant symptoms in the
areas of pain, stiffness and physical function in patients
with hip and/or knee OA. It consists of 24 questions in
three separated subscales: pain, physical function and stiff-
ness. Each subscale score weighed 10 points, and the
WOMAC global scale is the sum of the three subscales
and ranges from 0 to 30 [15]. The Lequesne index is a 10-
question interview-style survey that includes evaluation of
pain or discomfort, maximum walking distance and daily
activities performance. The total questionnaire is scored
on a 24 points scale [16].
Joint space width changes were assessed on radio-
graphs that followed standardized techniques [17]. Ateach time point 4 knee radiographs were obtained per
patient, to get from each knee a standing anterior-
posterior and lateral views. All radiographs were taken
by the same technician and were interpreted by 2 inde-
pendent physicians who were blinded to treatment, both
with certifications in orthopedics and traumatology. The
outcome measure was the progression of joint space
narrowing as suggested by Abadie et al. [18]. One inde-
pendent collaborator, blinded to treatment measured
joint space width in radiographs by visual reading ac-
cording to a validated method [19] at the joint’s narrow-
est point using an X10 magnifying lens graduated at
0.1 mm intervals.
Safety evaluation
The safety of experimental treatments was assessed with
reported adverse events, defined as any unfavorable and
unintended sign, symptom, or disease temporary present
during the intervention period, whether or not related to
the treatment. Adverse events were either reported by the
patient or discovered by physicians during visits. Adverse
events were classified into light, moderate, serious and le-
thal according to the Mexican Official Norm for Drug
Surveillance [20]. In addition patients were monitored
with laboratory tests (hematology, biochemistry and urine
analysis) at baseline, 12 and 18 months.
Statistical analysis
Baseline demographic variables and treatments’ compli-
ance were analyzed with the chi square test. The collected
data were analyzed in an intention-to-treat basis with sub-
jects that received the allocated intervention and attended
to at least one post-treatment evaluation. The WOMAC,
and Lequesnes´s functional indexes’ mean values were cal-
culated for each evaluation and a Student T test was used
to evaluate the significance of changes at each post-
treatment evaluation compared with baseline evaluation.
Mean changes between both treatments at each evaluation
were compared with ANOVA.
In the radiographies' analysis, the narrowest joint space
from both measurements in each knee was selected for
analysis. Mean values were calculated for both knees joint
spaces and a paired T-test was performed to evaluate joint
space change for each treatment. To evaluate the response
between treatments, a Generalized Estimating Equation
model was performed to evaluate joint space changes, this
model considered the correlation between each subject’s
knees and the baseline values as a covariate.
To evaluate safety of the treatment, adverse events
were classified by seriousness and were quantified to get
the incidence of each adverse event.
All statistical models were tested at the 0.05 level of
significance. Analyses were performed with SPSS® for
Windows version 18.0 (IBM®).
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A total of 123 patients were initially screened for the
study between December 2007 and February 2008, 50
did not meet the inclusion criteria or refused to partici-
pate. A total of 74 subjects were randomly assigned to
one of the two treatment groups, one refused to receive
the allocated intervention, 21 refused to continue at
some point during the trial due to personal reasons and
1 due to a rash that according with the physician should
not continue with the treatment. Thus, 51 patients fin-
ished the intervention and follow up period (Figure 1).
The baseline demographic characteristics of the pa-
tients that initiated the study and the patients that com-
pleted the study did not differ among the experimental
groups (Table 1). The majority of patients were female
(61/73), mean ± SD age was 54.9 ± 9.3 years. The body
mass index mean was 31.6 ± 4.7 Kg/m2. Baseline radio-
graphic analysis showed no significant difference among
treatment groups in joint-space narrowing and marginal
osteophytes formation, within each knee compartment.
In the majority of the patients (59/73), pain intensity in
the target knee was reported from moderate to severe.
After one year in the study 27 and 29 subjects from
SBCG1 and SBCG2, respectively, finished the interven-
tion period (Figure 1); all of them received the allocated
intervention. Most of the drop outs (85%) wereFigure 1 Flow of patients through the study.voluntary for personal reasons, which are expected due
to the long duration of the study. The statistical power
with the subjects that finished the study was above 90%.
Baseline and unadjusted as well as adjusted mean
changes of the WOMAC subscales and global scores at
different time points until 18 months are shown in Table 2.
At the end of the intervention, patients in SBCG1 and
SBCG2 groups, showed a significant improvement com-
pared with their baseline values in all WOMAC subscales:
81% and 77% in pain, 92% and 79% in stiffness and 90%
and 81% in physical functioning, respectively. The changes
in WOMAC total score along the period of treatment are
shown in Figure 2. The mean score that decreased at
12 months was maintained 6 months after treatment sus-
pension. There was no difference within treatments dur-
ing intervention or during post-treatment period.
Baseline values and unadjusted and adjusted mean
changes of the Lequesne functional index subscales and
global scores at different time points until 18 months
are shown in Table 3. After 12 months of treatment, pa-
tients in both groups showed a significant improvement
in all score subscales, for SBCG1 and SBCG2 groups,
there was a 74% and 69% reduction in pain, 74% and
71% improvement in maximum walking distance and
65% and 56% improvement in the daily activities sub-
scale, respectively. Figure 3 shows the changes in
Lequesne´s functional Index along the study period.
During the first 3 months of intervention the Lequesne´
s functional index score decreased substantially and
from month 4 to month 12 the improvement was main-
tained. After intervention period there was a reduction
in the Lequene´s total score of about 68% and 69% with
SBCG1 and SBCG2 groups, respectively, compared with
baseline values. There was no difference within treat-
ments during intervention and post-intervention period.
Joint space narrowing, within the knee joint during
treatment with intra-articular administration of SBCG1
and SBCG2 is shown in Figure 4. After the 12 month-
period of treatment there was a significant decrease in
joint-space width of −0.37 (95% CI: −0.64, −0.10) mm in
SBCG1 group, and there was no significant change in
SBCG2 group: 0.15 (−0.33, 0.63) mm. The mean joint
space change of SBCG2 was significantly higher than
SBCG1 group after 4 and 18 months.
The percentage of patients who experienced any ad-
verse event, during this study did not differ between
both groups (32% and 37% for SBCG1 and SBCG2, re-
spectively). The majority of adverse events (77%) were
related to knee OA: knee pain, nuisance or weakness,
stiffness, burning and numbness. The rest of the events
were not related with the knee or the intervention: re-
spiratory or gastrointestinal infections, headache and
lumbar pain among others. None of the reported adverse
events was classified as severe. The laboratory tests
Table 1 Baseline demographic characteristics of patients with osteoarthritis of the knee, by study groupa
Variables Baseline sample Final sample
SBCG1 SBCG2 Sig.b SBCG1 SBCG2 Sig.b
N 36 37 25 26
Age, y 55.22 ± 9.75 54.59 ± 8.98 0.775 54.44 ± 9.34 53.81 ± 8.61 0.802
BMI kg/cm2 31.14 ± 4.86 31.98 ± 4.57 0.453 31.66 ± 5.24 32.44 ± 4.62 0.579
Female 88.9 78.4 0.226 92.0 80.8 0.244
Location and grade* of OA
Left knee: Grade II 19.4 19.4 0.858 24.0 24.0 1.000
Grade III 50.0 55.6 48.0 48.0
Grade IV 30.6 25.0 28.0 28.0
Right knee: Grade II 19.4 16.2 0.843 24.0 19.2 0.893
Grade III 50.0 56.8 48.0 53.8
Grade IV 30.6 27.0 28.0 26.9
aValues are % or mean ± SD.
bANOVA or Chi Square significance level of group comparisons.
*According to Kellgren-Lawrence classification of OA.
Table 2 Evaluation of the experimental formulation during 12 months of intervention and 6 months of follow up in
WOMAC subscales
WOMAC subscales SBCG1 SBCG2
Score Change from baseline Score Change from baseline
Pain
Baseline 5.8 (5.2, 6.4) a 5.6 (5.0, 6.2)
3 mo. 1.9 (1.1, 2.8) b −4.0 (−7.0, −5.1) 2.4 (1.7, 3.2) −3.2 (−3.9, −2.5)
8 mo. 1.6 (1.0, 2.2) −4.2 (−9.1, −5.1) 1.5 (1.0, 2.0) −4.0 (−4.9, −3.2)
12 mo. 1.1 (0.6, 1.7) −4.5 (−10.5, −5.3) 1.3 (0.8, 1.9) −4.5 (−5.2, −3.8)
18 mo. 1.2 (0.5, 1.9) −4.3 (−8.4, −5.3) 1.0 (0.5, 1.5) −4.8 (−5.6, −4.0)
Stiffness
Baseline 5.9 (5.0, 6.7) 6.3 (5.6, 7.0)
3 mo. 2.0 (1.3, 2.6) −4.2 (−9.0, −5.1) 2.1 (1.3, 2.9) −4.0 (−4.9, −3.2)
8 mo. 1.0 (0.5, 1.5) −4.8 (−9.3, −5.8) 1.5 (0.9, 2.0) −4.8 (−5.7, −3.8)
12 mo. 0.5 (0.2, 0.9) −5.2 (−10.7, −6.2) 1.3 (0.6, 2.0) −4.9 (−5.9, −4.0)
18 mo. 0.7 (0.0, 1.4) −5.0 (−7.9, −6.3) 1.1 (0.4, 1.7) −5.0 (−6.0, −4.0)
Physical functioning
Baseline 5.9 (5.2, 6.6) 6.2 (5.4, 6.9)
3 mo. 2.1 (1.5, 2.8) −3.8 (−7.6, −4.9) 2.1 (1.5, 2.8) −3.8 (−4.5, −3.1)
8 mo. 1.4 (0.9, 1.9) −4.6 (−10.2, −5.5) 1.5 (1.1, 2.0) −4.7 (−5.6, −3.9)
12 mo. 0.6 (0.4, 0.9) −5.1 (−13.3, −5.9) 1.2 (0.6, 1.7) −5.2 (−6.1, −4.3)
18 mo. 0.7 (0.3, 1.2) −4.8 (−9.6, −5.9) 1.0 (0.5, 1.4) −5.2 (−6.2, −4.3)
Global score
Baseline 17.5 (15.7, 19.3) 18.1 (16.3, 19.9)
3 mo. 6.0 (4.2, 7.9) −11.9 (−9.1, −14.7) 6.7 (4.7, 8.7) −11.1 (−13.1, −9.1)
8 mo. 4.2 (2.7, 5.6) −13.5 (−10.4, −16.1) 4.5 (3.1, 5.9) −13.6 (−15.9, −11.2)
12 mo. 2.3 (1.5, 3.1) −14.8 (−14.2, −17.0) 3.8 (2.1, 5.5) −14.6 (−16.9, −12.4)
18 mo. 2.6 (0.8, 4.4) −14.0 (−9.7, −17.1) 3.1 (1.5, 4.6) −15.0 (−17.5, −12.6)
aAll values are means (95% confidence interval).
bAll post-treatment measurements were significantly different from baseline value. There were no significant differences between treatments.
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Figure 2 Monthly changes in WOMAC pain index by treatment group. Means (±SEM) are adjusted for baseline values. All post-treatment mea-
surements were significantly different from baseline value. There were no significant differences between treatments.
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in patients.
Discussion
The purpose of this study was to evaluate the effectiveness
of a combination of sodium bicarbonate and calcium glu-
conate at physiological concentrations of 1:1 (Wt/Vol)
(SBCG1) and a concentration of 1:2 (Wt/Vol) (SBCG2)
administrated directly into the knee joint, on OA symp-
toms and joint space width, as well as the safety of the ex-
perimental treatments. The baseline values of the
WOMAC index of patients involved in this study corre-
sponded to symptoms of mild to moderate severity.
The study confirmed that both SBCG formulations im-
proved OA symptoms during and after a period of
12 months and that the effect was maintained for 6 add-
itional months without treatment. These improvements
exceeded those that have been considered clinically sig-
nificant [21-24]. According to a review of Raynauld et al.
[25], intra-articular injection of hyaluronate reduced
knee pain in patients with OA by 20-40% over 6–12
months. In another randomized, placebo controlled trial,
patients taking 1500 mg oral glucosamine sulfate daily
for three years showed significant reduction of 34.1% in
total WOMAC index compared with baseline values
[26]. In the present study, both treatment groups experi-
enced a reduction on the WOMAC global scale of 84%
which is a substantial functional improvement.
Similarly, both experimental groups improved the pain,
maximum walking distance and daily activities scores ac-
cording to Lequesne´s functional index. A reduction of
about 30% in Lequesne´s functional index has been de-
fined as an effective treatment [27]. In a 3-year, random-
ized double-blind study, a treatment with glucosaminesulfate produced a reduction of about 20% in the
Lequesne´s index total score [28]. In another study, five
weekly intra-articular injections of hyaluronate produced
a reduction of 45% after 6 months (from 10.3 ± 3.7 points
at baseline to 5.7 ± 3.2 points after treatment) [29]. In the
present study, the mean improvement in the Lequesne´s
global score after 12 months was of 70 and 64% for
SBCG1 and SBCG2 groups, respectively. These changes
are above the values used to define treatment effectiveness
and more effective than previous studies. No further
changes were observed during the 6 months follow-up
period which shows that the benefits of the administration
of this solution will remain for at least six months.
The effect of the experimental treatments on joint
space width, was evaluated by measuring the change in
width of medial tibio-femoral joints’ space since it is the
primary outcome recommended by several authors
[17,30,31]. After one year of treatment, a slight narrow-
ing of joint-space width was observed in the SBCG1
group. The SBCG2 group did not experience a narrow-
ing in joint space during the intervention period. Several
studies have assessed the natural narrowing of joint
space width in patients with OA, it has been observed a
joint-space width change of about −0.6 mm/year [32]. A
large long-term study has shown that a joint space nar-
rowing of no more than −0.1 mm/year could bring clin-
ical benefits [33]. The mean joint space narrowing in the
SBCG1 group was above that value (−0.37 mm), this
suggests that although SBCG1 relieves symptoms of OA,
the lower concentration of calcium gluconate does not
stop its natural progression. In contrast, administration
of SBCG2 prevented this naturally occurring joint space
narrowing (0.36 mm). This effect was evident after the
first year of treatment and remained after 6 months
Table 3 Evaluation of the experimental formulation during 12 months of intervention and 6 months of follow up in
Lequesne Functional Index subscales
Lequesne subscales SBCG1 SBCG2
Score Change from baseline Score Change from baseline
Pain
Baseline 5.4 (4.9, 5.9)a - 5.5 (5.1, 5.9) -
3 mo. 2.7 (2.1, 3.3)b −3.0 (−7.5, −3.8) 2.4 (1.8, 3.1) −2.9 (−3.6, −2.2)
8 mo. 2.0 (1.5, 2.6) −3.4 (−9.0, −4.1) 1.9 (1.3, 2.6) −3.5 (−4.3, −2.8)
12 mo. 1.4 (1.0, 1.9) −3.8 (−9.9, −4.6) 1.7 (1.1, 2.4) −3.9 (−4.6, −3.3)
18 mo. 1.3 (0.7, 1.9) −3.8 (−8.8, −4.7) 1.7 (1.0, 2.4) −4.0 (−4.7, −3.4)
Maximum walking distance
Baseline 4.2 (3.4, 5.1) - 4.2 (3.6, 4.8) -
3 mo. 1.8 (0.9, 2.6) −2.9 (−6.4, −3.8) 2.2 (1.5, 2.9) −1.9 (−2.7, −1.2)
8 mo. 1.2 (0.5, 1.9) −3.2 (−6.8, −4.2) 1.4 (0.8, 1.9) −2.9 (−3.7, −2.1)
12 mo. 1.1 (0.4, 1.8) −3.2 (−6.7, −4.2) 1.2 (0.6, 1.8) −3.3 (−4.1, −2.5)
18 mo. 0.7 (−0.1, 1.4) −3.3 (−6.0, −4.4) 0.7 (0.2, 1.2) −3.7 (−4.4, −2.9)
Daily activities
Baseline 8.0 (6.8, 9.2) - 7.5 (6.7, 8.3) -
3 mo. 4.0 (3.3, 4.8) −4.4 (−5.7, −6.0) 3.9 (3.3, 4.6) −3.7 (−4.6, −2.8)
8 mo. 3.5 (2.9, 4.2) −4.7 (−6.3, −6.2) 3.5 (2.9, 4.1) −4.2 (−5.2, −3.2)
12 mo. 2.8 (2.2, 3.4) −4.9 (−7.8, −6.2) 3.3 (2.6, 4.0) −4.7 (−5.8, −3.6)
18 mo. 2.8 (2.1, 3.6) −4.5 (−6.3, −6.0) 2.9 (2.2, 3.7) −5.0 (−6.4, −3.5)
Global score
Baseline 17.6 (15.5, 19.8) - 17.2 (15.9, 18.5) -
3 mo. 8.5 (6.7, 10.2) −10.3 (−8.6, −12.7) 8.6 (7.0, 10.2) −8.6 (−10.2, −6.9)
8 mo. 6.8 (5.2, 8.3) −11.3 (−8.7, −13.9) 6.8 (5.3, 8.3) −10.6 (−12.5, −8.8)
12 mo. 5.3 (3.8, 6.8) −11.9 (−10.4, −14.2) 6.2 (4.6, 7.8) −11.9 (−13.8, −10.0)
18 mo. 4.8 (3.1, 6.4) −11.6 (−8.9, −14.4) 5.3 (3.7, 6.9) −12.7 (−14.8, −10.5)
aAll values are means (95% confidence interval).
bAll post-treatment measurements were significantly different from baseline value.
There were no significant differences between treatments.
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calcium gluconate may decelerate joint space narrowing
or even widen the joint space. Calcium gluconate may
produce a similar or greater effect than glucosamine sul-
fate, a compound that has proved to modify the joint
structure, since several reported clinical trials have shown
a little change in joint-space width (~ −0.06 mm/year)
with glucosamine sulfate [26,34]. Therefore, the effect of
calcium gluconate on joint-space narrowing found in the
present study could be even more beneficial than glucosa-
mine sulfate in a longer term. Moreover, according to
Abadie et al. [18] SBCG2 may have the characteristics to
become a DMOADs. Thus, further research needs to be
performed to confirm the effect of the experimental treat-
ment in joint space narrowing compared with other po-
tential pharmacological drugs.
The experimental treatment was developed upon previ-
ous works on the beneficial effect of large doses ofbicarbonate on certain chronic joint diseases because of
its alkalinity. Schweiz et al. [10] administered intra-
articular isotonic sodium bicarbonate 1-29% in several
doses from 0.5 to 2.0 mL at 2-day intervals. Two to four
injections were administered depending on each patient’s
symptoms improvement. The knee-joint was the most
often and most successfully treated. Additionally, Beckett
in a US patent [35], described the use of an aqueous neu-
tral to mildly alkaline bicarbonate solution useful for pre-
venting and treating inflammatory diseases such as OA. It
has been documented in in-vitro studies that sodium bi-
carbonate activates the Na+-dependent Cl− -HCO3
− ex-
changer which promotes a recovery of the intracellular
pH of chondrocyte leading a normalization of intracellular
metabolic activities [36]; and as a result, a rearrangement
of the extracellular matrix is expected [37-39].
The effect of calcium gluconate in the treatment of in-
flammatory diseases was also reported previously. Walter
Figure 3 Monthly changes in Lequesne´s functional index by treatment group. Means (±SEM) are adjusted for baseline values. All post-treatment
measurements were significantly different from baseline value. There were no significant differences between treatments.
García-Padilla et al. BMC Musculoskeletal Disorders  (2015) 16:114 Page 8 of 10in a US patent [11] described the use of corticosteroid
combined with calcium gluconate for arthritis and other
rheumatic diseases that involved an inflammatory process.
Recently, Kang et al. demonstrated that calcium gluconate
has a protective effect against OA through inhibition of
COX-2 and related chondrocytes apptosis [40]. Calcium
compounds applied simultaneously with corticosteroids in
the treatment of rheumatic diseases, reduced inflamma-
tion. It has also been reported that calcium gluconate al-
lows the linkage between chondrals and bone proteins,
which avoids the hyperosmotic and acid conditions of the
extracellular matrix and allows recovery of the homeo-
static mechanisms of the cartilage [41].
The mechanism of action of the SBCG formulation
has not been fully elucidated yet. The effect of sodium
bicarbonate and calcium gluconate over clinical symp-
toms of OA and joint space could be due to its effectsFigure 4 Joint space width changes in patients completing the intervention
value in Paired T-test (p < 0.05). ƗSignificantly different from SBCG2 in a General
both knees from each subject, and also considered the baseline evaluation valuon cartilage metabolism, including stimulation of ana-
bolic activities, such as the synthesis of proteoglycans,
and the depression of catabolic activities such as the ef-
fects of caspase-3 and Poly-ADP ribose polymerase
(PARP) a key mediators of apoptosis of chondrocytes.
To clarify the precise mechanism by which SBCG for-
mulation produces a beneficial effect on knee OA, fur-
ther studies with longer follow-up period and different
designs are needed. Although significant therapeutic ef-
fects of intra-articular injection of SBCG for knee OA
were observed in this study, the following limitations
must be considered: 1) Since recruited patients attended
to the hospital to get an OA treatment, it was not appro-
priate to provide a placebo treatment, thus all patients
received treatment. 2) There was no active-control treat-
ment, a review of results from similar studies that use
the same evaluation scales was considered enough toand 6 months follow-up. Errors bars represent SEM. *Different to baseline
ized Estimating Equation model that considered the correlation between
es as a covariate.
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ment options. 3) The sample included a wide range of OA
severity and segmented analyses based on the severity of
OA were not possible to perform due to lack of statistical
power. 4) Another limitation of the study was that radio-
graphic views were used to assess joint structural changes;
it is known that magnetic resonance imaging is more ac-
curate; however significant differences were found with
the increased variability that radiographs could cause. The
findings in this study are applicable to Hispanic adults
with knee OA that are seeking for a treatment.Conclusion
The findings of the present study demonstrate that a com-
bination of sodium bicarbonate and calcium gluconate ad-
ministered once a month directly into the knee joint
produces a highly significant reduction of pain and im-
provement in physical function measured with WOMAC
total score and Lequesne´s functional index starting from
the first intervention. The experimental formulation‘s im-
provement is maximized until 10 to 12 months; and its
beneficial effect is maintained for at least 6 months after
the administration is discontinued. Only when the dose of
calcium gluconate is increased, it eliminates further nar-
rowing of joint space. Although the possible mechanism is
not known at present, the administration of these two
physiological substances in combination represents a highly
effective and safe alternative for the treatment of knee OA.Abbreviations
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